March 21, 2001
Irvine biopharmaceutical company NeoTherapeutics Inc. incurred a net loss of $11.5 million, or 88 cents a share, for the fourth quarter, down from a net loss of $12.2 million, or $1.47 a share, for the 1999 fourth quarter, which included a charge of $2.5 million for a legal settlement. For the year, the company posted a net loss of $46.4 million, or $4.37 a share, compared with a 1999 net loss of $26 million, or $3.68 a share. The development-stage company reported no revenue.
March 20, 2001 |
Investors swept up shares of NeoTherapeutics Inc. on Monday after the Irvine biopharmaceutical company announced a license agreement with Pfizer Inc. worth up to $12 million. NeoTherapeutics, which until now has not generated revenue, will receive an initial payment from Pfizer.
February 8, 2001 |
NeoTherapeutics Inc.'s climbing stock moved up an additional 30% Wednesday, snapped up by investors after the company said it is planning a pivotal study of its drug compound for treating Alzheimer's disease. The Irvine biopharmaceutical company also said this week that a subsidiary received $7 million in new financing. The stock, which rose 15% on Tuesday and 14% on Monday, closed Wednesday at $4.16, up 97 cents a share in Nasdaq trading. A total of 1.
January 3, 2001 |
NeoTherapeutics Inc. filed a shelf registration statement with the Securities and Exchange Commission to issue up to $50 million of debt securities, stock, depositary shares or warrants. The Irvine biopharmaceutical company said Tuesday the filing allows it "speed and flexibility" when market conditions are attractive. A shelf filing lets the company register securities in advance and sell them from time to time as needed.
November 4, 2000
The Irvine biopharmaceutical incurred a third-quarter net loss of $13.2 million, or $1.27 a share, which included a noncash charge of $1 million from the sale of convertible preferred stock of its NeoGene unit. The net loss for the same period last year was $5.3 million, or 70 cents a share. Revenue was not reported.
October 27, 2000 |
NeoTherapeutics Inc., an Irvine biopharmaceutical company, said Thursday that data from a clinical study showed that Alzheimer's patients who took Neotrofin had a statistically significant improvement over the course of 90 treatment days. After the company's news release, the stock rose 75 cents, or 11%, to close at $7.75 in Nasdaq trading. The price went as high as $8.06 a share.